

## **AGC to Manufacture COVID-19 Vaccine for AdaptVac**

Tokyo, May 14, 2020—AGC (Headquarters: Tokyo; President: Takuya Shimamura) has announced that AGC Biologics (Headquarters: US), a CDMO\*<sup>1</sup> subsidiary of AGC, is partnering with Denmark-based AdaptVac to manufacture a candidate COVID-19 vaccine. The vaccine is being developed by AdaptVac to begin clinical trials in the second half of 2020.

As a member of PREVENT-nCoV, a E U Horizon 2020 sponsored consortium , AdaptVac is focusing efforts on development of a vaccine for the COVID-19 virus.

AdaptVac's virus like particle (VLP) \*<sup>2</sup> technology, which has achieved a high level of safety and effectiveness, is drawing significant attention as a candidate vaccine that could effectively protect the human body from COVID-19 infection.

AGC Biologics, a CDMO subsidiary of AGC, utilizes mammalian and microbial cells and in production to provide a variety of high value-added services that range from process development to upscaling, clinical trials, and commercial drug manufacturing. The company was selected as a manufacturing partner for COVID-19 vaccines in recognition of its high-level quality and services.

The AGC Group is committed to helping prevent the spread of COVID-19 and end this pandemic by playing a role in the manufacture of COVID-19 vaccines and drugs for pharmaceutical companies.

### Notes:

\*1 CDMO: Contract Development & Manufacturing Organization. A company which is contracted or acts on behalf of another company to handle product manufacturing as well as the development manufacturing methods.

\*2 Virus like particle (VLP): Because VLPs are similar in structure to viruses, they are anticipated to provide strong immunity as vaccines. Due also to their excellent safety in preventing virus proliferation in the body, they are attracting significant interest as a promising vaccine technology.

### REFERENCE

#### ■ About AdaptVac

AdaptVac is a joint venture between ExperS2ion Biotech and University of Copenhagen's spin -out venture NextGen Vaccines ApS, whose aim is to develop therapeutic drugs and vaccines for treating and preventing infectious diseases, cancer and immune disorders. Visit the URL below for more details.

URL : <http://www.adaptvac.com>

---

### MEDIA INQUIRIES

Kazumi Tamaki, General Manager, Corporate Communications & Investor Relations Division  
AGC Inc.

(Contact: Yuki Kitano; Tel: +81-3-3218-5603; E-mail: [info-pr@agc.com](mailto:info-pr@agc.com))

\*Handling of personal information is governed by our privacy policy.